Covidien Unit To Buy Specialty Drug Co. For $100M
Mallinckrodt, the St. Louis-based unit that will spin off from Covidien sometime next year, will buy all of CNS’ outstanding capital stock and expects the deal to close in the fourth quarter of 2012.
St. Paul, Minn.-based CNS develops and commercializes products for site-specific administration to the central nervous system to treat neurological disorders and intractable chronic pain, according to Mallinckrodt. The company...
To view the full article, register now.